IMMUNOTHERAPY USING HEAT SHOCK PROTEIN PREPARATIONS OF LEUKEMIC CELLS AFTER SYNGENEIC BONE MARROW TRANSPLANTAION IN MICE.
| Project/Area Number |
10670931
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | ASAHIKAWA MEDICAL COLLEGE |
|---|
Principal Investigator |
TORIMOTO Yoshihiro Asahikawa Medical College, Third Department of Internal Medicine, Instructor, 医学部, 助手 (00281882)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOHGO Yutaka ASAHIKAWA MEDICAL COLLEGE, THIRD DEPTARTMENT OF INTERNAL MEDICINE, PROFESSOR, 医学部, 教授 (10133183)
|
|---|
| Project Period (FY) |
1998 – 1999
|
| Project Status |
Completed (Fiscal Year 1999)
|
| Budget Amount *help |
¥3,000,000 (Direct Cost: ¥3,000,000)
Fiscal Year 1999: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 1998: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | Hert shock protein / HSP / Hematopoietic stem cell transplantation / Tumor Immunology / CD62L / minimal residual dedease / mouse / Immunotherapy |
|---|
| Research Abstract |
Heat shock proteins (HSPs) are the molecular chaper one, which bind endogeneous antigenic peptides and bring them to the major histocompatibility complex. Since HSPs chaper on a broad repertoire of endogeneous peptides, and the identification of each tumor specific antigen is not necessary, the strategy using HSPs is more advantageous than other immunological treatment procedures. In this study, we analyzed the immunotherapy with HSP preparations, HSP70 and GP96 derived from syngeneic leukemic cell lines A20, against minimal residual A20 cells during the reconstitution periods of immune system after syngeneic bone marrow transplantation in mice. All mice without immunization died within 60 days after A20 inoculation in this system. Whereas survival days in HSPs immunized mice were significantly prolonged. In addition, depletion of either CD4+ or CD8+ T lymphocyte significantly abrogated this efficacy of HSPs immunization, indicating that immunization with HSPs required CD4+ and CD8+ T lymphocytes in the effector phase of tumor immunity. Moreover, vaccination of HSP preparations derived from A20 elicited responses of potent cytotoxic T lymphocytes activities specific against A20 and led to memory CD4 T cell responses. These observations may suggest that the complex of HSPs and peptide derived from leukemic cells lead to specific immunity for mice with preexisting minimal amount of leukemic cells after syngeneic bone marrow transplantation.
|
Report
(3 results)
Research Products
(3 results)
